Policies: Not for routine commissioning
A commissioning policy is a document that defines access to a service for a particular group of patients. A NICE Technology Appraisal Guideline on the same topic will replace, or be incorporated into, a commissioning policy as appropriate. These are important documents that are developed to ensure consistency in access to treatments nationwide.
The following policies are not for routine commissioning.
- 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed-tomography (PET CT) as part of radical radiotherapy treatment planning for oesophageal cancer (all ages)
- Amifampridine phosphate for the treatment of Lambert-Easton myasthenic syndrome
- Argus II retinal prosthesis for retinitis pigmentosa
- Autologous chrondrocyte implantation for osteochondral lesions of the talus (adults)
- Bendamustine for refractory and relapsed mantle cell lymphoma
- Bortezomib for relapsed/refractory mantle cell lymphoma
- Bortezomib for relapsed / refractory Waldenstrom’s Macroglobulinaemia (all ages)
- Bortezomib for the treatment of refractory antibody mediated rejection post kidney transplant
- Chemosaturation for liver metastases from ocular melanomas
- Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation
- Continuous aztreonam lysine for cystic fibrosis (all ages)
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma
- Deep brain stimulation for central post stroke pain
- Deep brain stimulation for chronic neuropathic pain
- Deep brain stimulation for refractory epilepsy
- Deep brain stimulation for refractory Tourette Syndrome (adults)
- Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages)
- Eculizumab for the treatment of refractory antibody mediated rejection post kidney transplant
- Everolimus for prevention of organ rejection following heart transplantation
- Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above)(effective until 31 March 2019)
- Extra corporeal membrane oxygenation service for adults with cardiac failure
- Fampridine for multiple sclerosis
- Gastroelectrical stimulation for gastroparesis
- High definition silicone covers for prosthetic limbs, high definition feet and partial hand prosthesis
- Human coagulation factor X for hereditary factor X deficiency (all ages) (effective until 31 March 2019)
- Human coagulation factor X for hereditary factor X deficiency (all ages) (effective from 1 April 2019)
- Hyperbaric oxygen therapy for carbon monoxide poisoning (all ages)
- Hyperbaric oxygen therapy for diabetic lower limb ulceration (diabetic foot ulcer) (all ages)
- Hyperbaric oxygen therapy for malignant otitis externa (all ages)
- Hyperbaric oxygen therapy for necrotising soft tissue infections (all ages)
- Hyperbaric oxygen therapy for soft tissue radiation damage in patients with a history of pelvic irradiation for malignant disease (all ages)
- Infliximab (remicade) as anti-TNF Alpha treatment option for paediatric patients with severe refractory uveitis
- Infliximab for Progressive Pulmonary Sarcoidosis in adults
- Infliximab for the treatment of hidradenitis suppurativa
- Intrathecal pumps for treatment of severe chronic pain
- Multi-grip upper limb prosthetics
- Pasireotide for acromegaly as third-line treatments (adults)
- Personalised external aortic root support for surgical management of enlarged aortic root
- Proton beam therapy for cancer of the prostate
- Renal denervation for resistant hypertension
- Rituximab for chronic inflammatory demyelinating polyradiculoneuropathy
- Rituximab for connective tissue disease associated with interstitial lung disease
- Rituximab for the treatment of idiopathic membraneous nephropathy in adults
- Rituximab for the treatment of primary Sjogren’s syndrome in adults
- Robotic assisted lung resection for primary lung cancer
- Robotic assisted surgery for bladder cancer
- Robotic assisted surgery for oesophago-gastric cancers
- Robotic assisted trans-oral surgery for throat and voice box cancers
- Sapropterin in children with phenylketonuria (effective until 31 March 2019)
- Sapropterin for phenylketonuria (all ages) (effective from 1 April 2019)
- Selective internal radiation therapy (SIRT) for the treatment of chemotherapy refractory or intolerant, unresectable primary intrahepatic cholangiocarcinoma (all ages)
- Selexipag for the treatment of pulmonary arterial hypertension (all ages) (effective until 31 March 2019)
- Stereotactic ablative radiotherapy as a treatment option for patients with hepatocellular carcinoma or cholangiocarcinoma
- Stereotactic ablative radiotherapy as a treatment option for patients with oligometastatic disease
- Stereotactic ablative radiotherapy as a treatment option for patients with renal cancer
- Stereotactic ablative radiotherapy in the treatment of previously irradiated tumours of the pelvis, spine and nasopharynx
- Stereotactic ablative radiotherapy in the treatment of prostate cancer
- Stereotactic radiosurgery for adults with Parkinson’s tremor and familial essential tremor
- Surgery for pectus deformity (all ages)
- Temperature controlled laminar airflow device for persistent allergic asthma
- Teriparatide for the treatment of osteogenesis imperfecta (adults)
- Ziconotide (intrathecal delivery) for chronic refractory cancer pain